Fulgent Genetics, Inc. (FLGT)
USD 18.74
(-3.6%)
USD 18.74
(-3.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -167.82 Million USD | -217.03% |
| 2022 | 143.4 Million USD | -71.74% |
| 2021 | 507.36 Million USD | 136.74% |
| 2020 | 214.31 Million USD | 58454.64% |
| 2019 | 366 Thousand USD | 108.15% |
| 2018 | -4.48 Million USD | -68.7% |
| 2017 | -2.66 Million USD | 50.61% |
| 2016 | -5.38 Million USD | 35.19% |
| 2015 | -8.31 Million USD | -94.12% |
| 2014 | -4.28 Million USD | 0.0% |
| 2001 | 104.33 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -13.46 Million USD | 89.5% |
| 2024 Q2 | -8.71 Million USD | 35.3% |
| 2023 Q1 | -15.84 Million USD | 34.17% |
| 2023 FY | -167.82 Million USD | -217.03% |
| 2023 Q4 | -128.14 Million USD | -877.71% |
| 2023 Q3 | -13.1 Million USD | -16.72% |
| 2023 Q2 | -11.22 Million USD | 29.15% |
| 2022 Q3 | 1.34 Million USD | -88.36% |
| 2022 FY | 143.4 Million USD | -71.74% |
| 2022 Q1 | 153.97 Million USD | 47.58% |
| 2022 Q2 | 11.53 Million USD | -92.51% |
| 2022 Q4 | -24.07 Million USD | -1892.7% |
| 2021 Q4 | 104.33 Million USD | -14.84% |
| 2021 FY | 507.36 Million USD | 136.74% |
| 2021 Q1 | 200.69 Million USD | 20.68% |
| 2021 Q3 | 122.52 Million USD | 53.51% |
| 2021 Q2 | 79.81 Million USD | -60.23% |
| 2020 Q4 | 166.3 Million USD | 256.59% |
| 2020 Q1 | -1.95 Million USD | -560.81% |
| 2020 Q2 | 3.32 Million USD | 269.79% |
| 2020 Q3 | 46.63 Million USD | 1304.34% |
| 2020 FY | 214.31 Million USD | 58454.64% |
| 2019 Q2 | 331 Thousand USD | 117.35% |
| 2019 Q3 | 1.46 Million USD | 341.69% |
| 2019 Q4 | -296 Thousand USD | -120.25% |
| 2019 FY | 366 Thousand USD | 108.15% |
| 2019 Q1 | -1.9 Million USD | -104.06% |
| 2018 Q3 | -595 Thousand USD | 43.28% |
| 2018 Q1 | -1.91 Million USD | -7.61% |
| 2018 FY | -4.48 Million USD | -68.7% |
| 2018 Q4 | -935 Thousand USD | -57.14% |
| 2018 Q2 | -1.04 Million USD | 45.08% |
| 2017 Q1 | 232 Thousand USD | -71.46% |
| 2017 FY | -2.66 Million USD | 50.61% |
| 2017 Q4 | -1.77 Million USD | -62.4% |
| 2017 Q3 | -1.09 Million USD | -4272.0% |
| 2017 Q2 | -25 Thousand USD | -110.78% |
| 2016 Q3 | -1.02 Million USD | 77.23% |
| 2016 Q1 | -543 Thousand USD | 93.65% |
| 2016 Q2 | -4.51 Million USD | -730.57% |
| 2016 Q4 | 813 Thousand USD | 179.16% |
| 2016 FY | -5.38 Million USD | 35.19% |
| 2015 Q1 | 425 Thousand USD | 0.0% |
| 2015 Q2 | 746 Thousand USD | 75.53% |
| 2015 Q4 | -8.54 Million USD | -2480.22% |
| 2015 Q3 | 359 Thousand USD | -51.88% |
| 2015 FY | -8.31 Million USD | -94.12% |
| 2014 FY | -4.28 Million USD | 0.0% |
| 2001 FY | 104.33 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 27.815% |
| Prenetics Global Limited | -62.72 Million USD | -167.562% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -10741.408% |
| CareDx, Inc | -190.28 Million USD | 11.803% |
| Exact Sciences Corporation | -204.14 Million USD | 17.793% |
| Exagen Inc. | -23.68 Million USD | -608.451% |
| Inotiv, Inc. | -105.14 Million USD | -59.621% |
| Guardant Health, Inc. | -479.44 Million USD | 64.996% |
| Biodesix, Inc. | -52.14 Million USD | -221.837% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -6283.502% |
| Precipio, Inc. | -5.85 Million USD | -2767.333% |
| iSpecimen Inc. | -11.09 Million USD | -1412.007% |
| Natera, Inc. | -434.8 Million USD | 61.402% |
| Aspira Women's Health Inc. | -16.69 Million USD | -905.542% |
| Standard BioTools Inc. | -74.65 Million USD | -124.798% |
| 23andMe Holding Co. | -666.7 Million USD | 74.828% |
| Castle Biosciences, Inc. | -57.46 Million USD | -192.042% |
| Personalis, Inc. | -108.29 Million USD | -54.969% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -89.673% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -1587.182% |
| OpGen, Inc. | -32.66 Million USD | -413.721% |
| T2 Biosystems, Inc. | -50.07 Million USD | -235.134% |
| Myriad Genetics, Inc. | -112 Million USD | -49.844% |
| ICON Public Limited Company | 612.33 Million USD | 127.407% |
| NeoGenomics, Inc. | -87.96 Million USD | -90.78% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -10741.408% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 119.86% |
| RadNet, Inc. | 3.04 Million USD | 5613.305% |
| MDxHealth SA | -43.1 Million USD | -289.385% |
| Psychemedics Corporation | -4.15 Million USD | -3940.082% |
| Illumina, Inc. | -1.16 Billion USD | 85.545% |
| Check-Cap Ltd. | -17.56 Million USD | -855.288% |
| Twist Bioscience Corporation | -208.72 Million USD | 19.596% |
| DarioHealth Corp. | -59.42 Million USD | -182.405% |
| Sera Prognostics, Inc. | -36.24 Million USD | -363.068% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -1568.199% |
| OPKO Health, Inc. | -188.86 Million USD | 11.139% |
| Medpace Holdings, Inc. | 282.81 Million USD | 159.342% |
| Neogen Corporation | -9.42 Million USD | -1681.393% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -1552.348% |
| Prenetics Global Limited | -62.72 Million USD | -167.562% |
| Mainz Biomed B.V. | -26.29 Million USD | -538.222% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -2014.461% |
| Trinity Biotech plc | -24.01 Million USD | -598.747% |
| Neuronetics, Inc. | -30.18 Million USD | -455.914% |
| Sotera Health Company | 51.37 Million USD | 426.66% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -2014.461% |